Propanc Biopharma’s cancer treatment granted patent in India

Australia-located Propanc BiopharmaInc., a clinical stage biopharmaceutical company focusing on development of treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, has announced that Propanc’s foundation patent application has been granted by the Office of the Controller General of Patents, Design and Trademarks, India.

The foundation patent, which covers the company’s lead product candidate, PRP, pioneers the discovery of a pharmaceutical composition for treating cancer via a combination of trypsinogen and/or chymotrypsinogen pancreatic proenzymes.

“Building a robust patent portfolio has been a top priority in driving our drug development technology forward. Adding India to the growing list of countries where we have been granted patents reflects the strength of our growing IP portfolio for PRP,” said James Nathanielsz, Propanc’s Chief Executive Officer.

Recommended News